Literature DB >> 34754209

Timing and Efficacy of 595-nm Pulsed-Dye Laser Combined with 0.5% Timolol Maleate Solution in the Treatment of Superficial Infantile Hemangiomas.

Weikang Shi1, Huiyi He1, Jicong Jiang1, Yu Gao1, Hehe Quan1.   

Abstract

PURPOSE: Infantile hemangioma (IH) is the most common benign tumor in infancy, and superficial IH is the most common type. IH can reportedly resolve spontaneously, but this is associated with complications, such as scars, atrophy, hypopigmentation, telangiectasia, and skin sagging, in 70% of cases. This study explores the safety and feasibility of therapeutic intervention with the 595-nm pulsed-dye laser (PDL) combined with 0.5% timolol maleate solution in superficial IH and compares the difference in efficacy between the early group and the late group. PATIENTS AND METHODS: This retrospective study examined 167 patients with superficial IH who underwent combination therapy at the Dermatology Clinic of the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University between July 2019 and July 2020. The early and late groups were composed of children aged ≤2 and >2 months, respectively. Treatment was administered for 6 months, and patients were followed up for another 6 months. Two independent, double-blinded physicians reviewed photographs of the skin lesions before and after treatment to evaluate efficacy.
RESULTS: The early group demonstrated higher treatment efficacy than the late group. The early (n = 45) and late (n = 122) groups had treatment efficacy rates of 95.5% and 86.1%, respectively; the difference was statistically significant (P< 0.05). The early and late groups underwent 3.51 ± 0.50 and 4.73 ± 0.68 months of treatment, respectively; the difference was statistically significant (P< 0.05). Seventeen (44.4%) patients in the early group had immediate adverse reactions but no permanent sequelae, whereas 25 (20.49%) and 13 (10.7%) patients in the late group had immediate and permanent sequelae, respectively. The difference was statistically significant (P<0.05).
CONCLUSION: This retrospective study demonstrated that 595-nm PDL combined with 0.5% timolol maleate solution was a safe and effective local treatment for superficial IH. Early treatment required fewer treatments, had better curative effects, and a lower probability of permanent sequelae.
© 2021 Shi et al.

Entities:  

Keywords:  infantile hemangiomas; pulsed-dye laser; timing and efficacy; timolol maleate solution

Year:  2021        PMID: 34754209      PMCID: PMC8572025          DOI: 10.2147/CCID.S337850

Source DB:  PubMed          Journal:  Clin Cosmet Investig Dermatol        ISSN: 1178-7015


  27 in total

1.  Prospective, open-label, rater-blinded and self-controlled pilot study of the treatment of proliferating superficial infantile hemangiomas with 0.5% topical timolol cream versus 595-nm pulsed dye laser.

Authors:  Hanru Ying; Yun Zou; Wenxin Yu; Yajing Qiu; Gang Ma; Lei Chang; Yifei Gu; Dongze Lyu; Xiaoxi Lin
Journal:  J Dermatol       Date:  2017-02-13       Impact factor: 4.005

2.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

Review 3.  Incidence and treatment of infantile haemangioma in preterm infants.

Authors:  Rangmar Goelz; Christian F Poets
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2014-10-28       Impact factor: 5.747

4.  Efficacy and safety of adrenergic beta-antagonist combined with lasers in the treatment of infantile hemangiomas: a meta-analysis.

Authors:  Xingfan Chen; Yu Guo; Pu Wang; Fengzhen Qiu; Yuming Sun; Qingmei Shi; Yuyan Deng; Chengjun Hu; Shaorong Lei
Journal:  Pediatr Surg Int       Date:  2020-07-09       Impact factor: 1.827

Review 5.  Hemangioma update: pearls from 30 years of treatment.

Authors:  Barry M Zide; Steven M Levine
Journal:  Ann Plast Surg       Date:  2012-07       Impact factor: 1.539

6.  Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study.

Authors:  Ajith Chakkittakandiyil; Rod Phillips; Ilona J Frieden; Elaine Siegfried; Irene Lara-Corrales; Joseph Lam; James Bergmann; Philip Bekhor; Solmaz Poorsattar; Elena Pope
Journal:  Pediatr Dermatol       Date:  2011-12-09       Impact factor: 1.588

Review 7.  Treatment of infantile haemangiomas: recommendations of a European expert group.

Authors:  Peter H Hoeger; John I Harper; Eulalia Baselga; Damien Bonnet; Laurence M Boon; Marta Ciofi Degli Atti; Maya El Hachem; Arnold P Oranje; Agneta Troilius Rubin; Lisa Weibel; Christine Léauté-Labrèze
Journal:  Eur J Pediatr       Date:  2015-05-29       Impact factor: 3.183

8.  The current management of vascular birthmarks.

Authors:  O Enjolras; J B Mulliken
Journal:  Pediatr Dermatol       Date:  1993-12       Impact factor: 1.588

9.  Growth characteristics of infantile hemangiomas: implications for management.

Authors:  Linda C Chang; Anita N Haggstrom; Beth A Drolet; Eulalia Baselga; Sarah L Chamlin; Maria C Garzon; Kimberly A Horii; Anne W Lucky; Anthony J Mancini; Denise W Metry; Amy J Nopper; Ilona J Frieden
Journal:  Pediatrics       Date:  2008-08       Impact factor: 7.124

10.  Clinical efficacy of the 595 nm pulsed dye laser in the treatment of childhood superficial hemangioma - analysis of 10-year application in Chinese patients.

Authors:  Wei Chen; Shengxiu Liu; Chunjun Yang; Sen Yang
Journal:  J Dermatolog Treat       Date:  2013-11-20       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.